FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Deals news from FierceBiotech

News

Elan wins $55M judgment in patent scrap

Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Read more...

Report: Pfizer makes counter-offer for Ranbaxy

Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...

Lilly pays $35M to land TransPharma pact

Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...

Symphogen inks $330M collaboration pact with Genentech

Denmark's Symphogen has inked a $330 million collaboration deal with Genentech to discover new antibodies for three infectious disease Read more...

Novo Nordisk discontinues Phase III on disappointing results

Concluding that a late-stage trial of its experimental therapy to prevent bleeding in trauma patients was headed to a likely failure, Novo Nordisk discontinued the study of Read more...

Pfizer blazes new research path

Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund Read more...
Tags: Pfizer  

Vertex shares rise on positive data for telaprevir

Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...

Ipsen inks a string of deals in expansion effort

France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...

Exelixis gets $150M credit line

Exelixis has struck a $150 million financing deal with Deerfield Management. At Exelixis discretion, the developer can draw down the money as needed over the next 18 months in $15 million Read more...